Potential effects of rational prescribing on national health care spending: More than half a billion dollars in annual savings. Littman, J. and Halil, R. Canadian Family Physician. March 2016, 62 (3) 235-244.
Merger Mania: Mergers and acquisitions in the generic drug sector from 1995 to 2016. Gagnon, M-A (principal author), Volesky, K. Globalization and Health. 2017 Aug; 13 (62): 1-7.
The role and impact of cost-sharing mechanisms for prescription drug coverage. Gagnon, M-A. Canadian Medical Association Journal 2017; 189 (19): E680-E681.
Cost effectiveness of continued warfarin versus heparin bridging therapy during pacemaker and defibrillator surgery. Coyle D, Coyle K, Essebag V, Birnie DH, Ahmad K, Toal S et al. Journal of American College of Cardiology 2015 Mar 10;65(9):957-9.
Economic evaluation of a hospital-initiated intervention for smokers with chronic disease, in Ontario, Canada. Mullen KA, Coyle D, Manuel D, Nguyen HV, Pham B, Pipe AL, Reid RD. Tobbaco Control. 2015;24(5):489-96.
EQUIPT: protocol of a comparative effectiveness research study evaluating cross-context transferability of economic evidence on tobacco control. Pokhrel S, Evers S, Leidl R, Trapero-Bertran M, Kalo Z, Vries Hd, Crossfield A, Andrews F, Rutter A, Coyle K, Lester-George A, West R, Owen L, Jones T, Vogl M, Radu-Loghin C, Voko Z, Huic M, Coyle D. BMJ Open. 2014 Nov 24;4(11):e006945
Application of a policy framework for the public funding of drugs for rare diseases. Winquist E, Coyle D, Clarke JTR, Evans GA, Seager C, Chan W, Martin J. J Gen Intern Med 2014 Aug;29 Suppl 3:S774-9.
Cost-effectiveness of new oral anticoagulants compared to warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S et al. Value in Health 2013;16(4):498-506
Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial). Reaume MN, Leighl NB, Mittmann N, Coyle D, Hirsh V, Seymour L et al. Lung Cancer. 2013 82(1):115-20.
Cost effectiveness of exercise programs in Type 2 diabetes. Coyle D, Coyle K, Kenny GP, Boulé NG, Wells GA, Fortier M, Reid RD, Phillips P, Sigal RJ. Int J Technol Assess Health Care. 2012 Jul;28(3):228-34.
How do Economic Evaluations Inform Health Policy Decisions for Treatment and Prevention in Canada and the United States? Husereau D, Culyer AJ, Neumann P, Jacobs P. Appl Health Econ Health Policy. 2014:13(3):273-9.
Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. Conly J, Clement F, Tonelli M, Hemmelgarn B, Klarenbach S, Lloyd A, Husereau D, et al CMAJ. 2011;183(16):E1180–8.
Value-Based Pricing of Pharmaceuticals in Canada: Opportunities to Expand the Role of Health Technology Asessment? Husereau D, Cameron CG. Ottawa: Canadian Foundation for Healthcare Improvement; 2011.
Direct costs of adult chronic rhinosinusitis using four methods of estimation: results of the US Medical Expenditure Panel Survey. Caulley L, Thavorn K, Rudmik L, Cameron C, Kilty SJ. Journal of Allergy and Clinical Immunology. 2015; 136(6):1517-22.
Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. Tawfik A, Bielecki JM, Krahn M, Dorian P, Hoch JS, Boon H, Husereau D, Pechlivanoglou P. Clin Pharmacol. 2016; 8:93-107.
The PIP-STOPP study: Assessing Potentially Inappropriate Prescribing in (PIP) and predicting patient outcomes using a subset of the STOPP criteria in Ontario’s older population: a population-based cohort study using large health administrative databases. Bjerre LM, Ramsay T, Cahir C, Ryan C, Halil R, Farrell B, Thavorn K, Catley C, Hawken S, Gillespie U, Manuel DG. BMJ Open. 2015;5:e010146.
Potentially Inappropriate Prescribing (PIP) in Long-Term Care (LTC) patients: validation of the 2014 STOPP-START and 2012 Beers criteria in a LTC population -- a protocol for a cross-sectional comparison of clinical and health administrative data. Bjerre LM, Halil R, Catley C, Farrell B, Hogel M, Black CD, Williams M, Ryan C, Manuel DG. BMJ Open. 2015;5:e009715.
Trends in antiparkinson drug use in the United States, 2001-2012. Crispo J, Fortin Y, Emons M, Bjerre LM, Kohen D, Perez Lloret S, Mattison D, Willis A, Krewski D. European Journal of Clinical Pharmacology. In Press, June 2015.
Antibiotics for community-acquired pneumonia in adult outpatients. (Cochrane Review Update). Pakhale S, Mulpuru S, Verheij TJ, Kochen MM, Rohde GG, Bjerre LM. Cochrane Database Syst Rev. 2014 Oct 9;10:CD002109.
Comparative effectiveness of monotherapies and combination therapies for patients with hypertension: protocol for a systematic review with network meta-analysis. Hutton B, Tetzlaff J, Yazdi F, Thielman J, Kanji S, Fergusson D, Bjerre LM, Mills E, Thorlund K, Tricca A, Straus S, Moher D, Lennen F HH. Systematic Reviews. 2013; 2:44.
Influence of female gender on hepatitis C virus infection progression and treatment outcomes. Corsi DJ, Karges W, Thavorn K, Crawley AM, Cooper C. European Journal of Gastroenterology and Hepatology. 2016; In Press.
Identifying strategies to improve diabetes care in Alberta, Canada, using the knowledge-to-action cycle. Manns B, Braun T, Edwards A, Grimshaw J, Hemmelgarn B, Husereau D, et al. CMAJ Open. 2013;1(4):E142–50.
Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, et al. CMAJ. 2011;183(16):E1189–202.
A comparative study of the format, content and timing of medication safety letters issued in Canada, the US and the UK. Bjerre, LM et al. BMJ Open (accepted with revision). 2018.
New Drug Pricing; Does it make any sense? Gagnon M-A. Prescrire International 24 (162), 2015: 192-195. English translation of « Pourquoi les médicaments sont-ils si chers? Les dérives d’un modèle d’affaires. » Prescrire 35 (380), 2015: 457-461.
The Future of Drug Coverage in Canada. Morgan SG, Martin D, Gagnon M-A, Barbara Mintzes, Daw JR, Lexchin J. Pharmacare 2020; Published by the Pharmaceutical Policy Research Collaboration, University of British Columbia. July 15 2015.
How do Economic Evaluations Inform Health Policy Decisions for Treatment and Prevention in Canada and the United States? Husereau D, Culyer AJ, Neumann P, Jacobs P. Appl Health Econ Health Policy. 2014;13(3):273-9.
Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. Bjerre, LM et al. Canadian Family Physician. 2018; 64: 19-27 (online publication January 23rd, 2018)
Methodology for Developing Deprescribing Guidelines: Using Evidence and GRADE to Guide Recommendations for Deprescribing. Farrell B, Pottie K, Rojas-Fernandez C, Bjerre LM, Thompson W, Welch V. PLoS ONE. 2016; 11(8).
Effectiveness of personal protective equipment for healthcare workers caring for patients with filovirus disease: a rapid review. Hersi M, Stevens A, Quach P, Hamel C, Thavorn K, Garritty C, Skidmore B, Vallenas C, Norris SL, Egger M, Eremin S, Ferri M, Shindo N, Moher D. PLOS ONE. 2015; 10(10): 1-17.
The Increasing Burden and Complexity of Multimorbidity in Ontario, Canada. Pefoyo AJK, Bronskill SE, Gruneir A, Calzavara A, Thavorn K, Petrosyan Y, Maxwell CJ, Bai Y, Wodchis WP. BMC Public Health. 2015; 15(415): 1-11.
Upper gastrointestinal bleeding in elderly patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Thavorn K, Gomes T, Camacho X, Juurlink D, Zhan Y, Mamdani M. Journal of the American Geriatrics Society. 2014; 62:382-384.
This is a list of publications authored or co-authored by RTMP members fitting within the themes of RTMP.